Peptide Profile
Liraglutide
Victoza · Saxenda
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management and type 2 diabetes, formulated as a daily subcutaneous injection that reduces appetite by activating GLP-1 receptors in the…
- Half-life
- 13 hours
- Routes
- subcutaneous
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
What Liraglutide is
About Liraglutide
GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management and type 2 diabetes, formulated as a daily subcutaneous injection that reduces appetite by activating GLP-1 receptors in the hypothalamus and brainstem. It mimics endogenous incretin hormone action — slowing gastric emptying, increasing satiety signaling, and reducing caloric intake through central and peripheral GLP-1 receptor pathways. The landmark SCALE Obesity trial, a large multicenter randomized controlled trial published in the New England Journal of Medicine, demonstrated significant weight loss of approximately 8% at 56 weeks with 3.0 mg liraglutide (Saxenda) compared to placebo. Liraglutide is an FDA-approved prescription medication available as Victoza (type 2 diabetes, 1.8 mg) and Saxenda (chronic weight management, 3.0 mg); it requires physician supervision and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma. Liraglutide vs semaglutide: key distinctions Liraglutide is a daily subcutaneous injection; semaglutide is weekly. The dosing frequency difference reflects half-life: liraglutide's plasma half-life is approximately 13 hours, requiring daily administration to maintain therapeutic levels; semaglutide's albumin-binding modification extends its half-life to approximately 7 days. For weight management outcomes, semaglutide significantly outperforms liraglutide: STEP 1 reported ~15% mean weight reduction vs ~8% with liraglutide in SCALE. The practical implication is that liraglutide is generally appropriate for patients who have contraindications to once-weekly GLP-1 therapy, who are already established on liraglutide for T2D (Victoza), or who are in a jurisdiction where semaglutide is less accessible. Liraglutide has a longer post-approval safety record — it was approved in 2010 for T2D and 2014 for obesity management — while semaglutide's obesity indication was approved in 2021. The LEADER trial established cardiovascular risk reduction for liraglutide in T2D patients, adding an outcomes benefit beyond glucose control. Liraglutide cost and access: As a branded pharmaceutical (Victoza, Saxenda), liraglutide requires a prescription from a licensed provider. Saxenda (3.0mg/day for obesity) has an approximate monthly list price of $1,300–$1,500 USD; actual cost varies by insurance coverage and assistance programs. Generic liraglutide is now available in the US: the FDA approved a generic of Victoza (liraglutide for type 2 diabetes; Hikma) in December 2024, and a generic of Saxenda (liraglutide for weight management; Teva) was approved and launched in August 2025. Compounding pharmacies do not commonly produce liraglutide formulations given the availability of approved branded products. Providers offering GLP-1 agonist programs that include liraglutide are searchable in the PeptideBase provider directory.
Liraglutide Benefits & Research Areas
Research Signals
Commonly researched in the context of
Population research notes
These signals reflect research interest areas, not treatment indications.
Liraglutide half-life calculator
Compound & timing
Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.
What the evidence says about Liraglutide
Research Evidence
based on 15 studies · 2 RCTs · most recent 2026
Regulatory Status
- Availability Status
- Prescription
- FDA Status
- FDA Approved
- Effective Date
- January 25, 2010
- Source
- View FDA source →
FDA-approved GLP-1 agonist. Victoza (NDA 022341, Jan 2010) for T2D; Saxenda (NDA 206321, Dec 2014) for weight management. Prescription only. Generic liraglutide available (generic Victoza, Dec 2024; generic Saxenda, Aug 2025).
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
15 sources cited · 2 strong · 13 moderate
2 RCTs · 8 Cohorts · 5 Reviews
Semaglutide vs liraglutide for weight loss in adults with overweight or obesity
JAMA · 2022
The STEP 8 trial found that once-weekly subcutaneous semaglutide 2.4 mg reduced mean body weight by 15.8% compared with 6.4% for once-daily liraglutide 3.0 mg over 68 weeks in adults with overweight or obesity, providing direct comparative evidence for GLP-1 receptor agonist weight loss efficacy.
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
New England Journal of Medicine · 2015
The SCALE Obesity and Prediabetes trial found that once-daily liraglutide 3.0 mg reduced mean body weight by 8.4 kg compared with 2.8 kg for placebo over 56 weeks in adults with overweight or obesity, with 63.2% of participants achieving at least 5% weight loss.
Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.
Diabetes Obes Metab · 2026
# Summary Research found that among adults with overweight or obesity, subcutaneous GLP-1 receptor agonists—including liraglutide at higher doses—effectively reduced body fat and fat deposits while also producing reductions in lean mass that were most pronounced at higher treatment doses. This study demonstrated that while these medications substantially improve excess adiposity measures, their use is associated with unfavorable effects on lean tissue, particularly at elevated dosing levels.
Show 12 more sources ↓
GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.
Diabetes Res Clin Pract · 2026
Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.
J Anesth · 2026
Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.
J Anesth · 2026
Effects of the glucagon-like peptide-1 receptor agonist liraglutide on retinal endothelial function and oxidative stress during sepsis.
Front Pharmacol · 2026
GLP-1 Receptor Agonists and the Ocular Surface: A Narrative Review of Restoration, Remodeling, and Clinical Implications.
Ophthalmol Ther · 2026
GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.
Diabetes Res Clin Pract · 2026
Effects of the glucagon-like peptide-1 receptor agonist liraglutide on retinal endothelial function and oxidative stress during sepsis.
Front Pharmacol · 2026
GLP-1 Receptor Agonists and the Ocular Surface: A Narrative Review of Restoration, Remodeling, and Clinical Implications.
Ophthalmol Ther · 2026
GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.
Dis Mon · 2026
# Summary This systematic review found that GLP-1 receptor agonists, including liraglutide, demonstrated substantial weight loss and significant cardiovascular risk reduction in high-risk populations with obesity, diabetes, and cardiovascular disease. However, researchers observed that direct evidence regarding thromboembolic event reduction remains limited, though available data suggest potential benefits that require confirmation through larger future studies.
Beyond weight loss: multisystem benefits of obesity medications.
Lancet Diabetes Endocrinol · 2026
This systematic review of RCT and meta-analysis data found that liraglutide and other GLP-1 receptor agonists produce clinically meaningful multisystem benefits beyond weight loss, including improvements in type 2 diabetes, cardiovascular disease, metabolic liver disease, sleep apnoea, and depression, with growing evidence for direct weight-independent receptor-mediated effects.
Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database.
Pharmacol Rep · 2026
# Summary Research found that among glucagon-like peptide-1 receptor agonists analyzed in European pharmacovigilance reports, semaglutide showed a lower reporting rate of thyroid cancer-related adverse events compared to tirzepatide, though the study's authors emphasized that these findings require cautious interpretation and further investigation to establish any causal relationship. This study demonstrated that gastrointestinal and general disorders were the most commonly reported adverse events across these medications, with the majority of cases occurring in adult and elderly female patients.
GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.
Dermatol Surg · 2026
# Summary Research found that patients taking GLP receptor agonists experienced significantly reduced rates of postoperative inflammatory complications within one month following dermatologic surgery, compared to those not using these medications. This study demonstrated that among the GLP medications examined, semaglutide and tirzepatide showed the greatest reductions in complications such as infection, wound disruption, and hematoma.
Liraglutide Side Effects & Safety Considerations
Contraindications below are derived from the compound’s FDA label. Educational only — not medical advice.
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Absolute contraindications
Warnings & cautions
Source: FDA label
Common monitoring markers in research protocols
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSLiraglutide
Frequently Asked Questions — Liraglutide
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management and type 2 diabetes, formulated as a daily subcutaneous injection that reduces appetite by activating GLP-1 receptors in the hypothalamus and brainstem. It mimics endogenous incretin hormone action — slowing gastric emptying, increasing satiety signaling, and reducing caloric intake through central and peripheral GLP-1 receptor pathways.
appetite suppression, weight loss, blood sugar regulation.
Research on Liraglutide primarily documents effects related to appetite suppression and weight loss and blood sugar regulation. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Liraglutide include Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), Known hypersensitivity to the drug or excipients. 7 additional considerations are noted in the safety profile above. This is educational information only — consult a qualified healthcare professional before use.
For Liraglutide, its FDA status is FDA-approved, and it is available by prescription. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
47 providers in the directory currently offer Liraglutide.
The STEP 8 trial found that once-weekly subcutaneous semaglutide 2.4 mg reduced mean body weight by 15.8% compared with 6.4% for once-daily liraglutide 3.0 mg over 68 weeks in adults with overweight or obesity, providing direct comparative evidence for GLP-1 receptor agonist weight loss efficacy.
How to get Liraglutide
Where to buy Liraglutide
47 providersTelehealth Platforms
1 providerClinics
9 providersFunctional Medicine Partners
Vancouver, United StatesView →Medical Health Institute
Palmetto Bay, United StatesView →OMNI SCULPT MD
Dallas, United StatesView →Optimal Hormone Health
Salt Lake City, United StatesView →Slim Weight Loss Clinic
Heald Green, United KingdomView →Austin Regenerative Therapy
Austin, United StatesView →Newcastle Weight Loss Injections from £23/week
New Lambton Heights, United KingdomView →Optimal Hormones Medical
Scottsdale, United StatesView →Premier TRT
Thornton, United StatesView →
Questions to ask your provider
Stay updated on verified Liraglutide providers
New verified providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.